New to Bioss? Enjoy 35% of your first order. Use code "FirstOrder35" - Offer valid for new U.S. Customers on direct orders only

Beta catenin Polyclonal Antibody, PE Conjugated

Applications

  • WB
  • FCM

Reactivity

  • Human
  • Mouse
  • Rat
  • Pig
  • Zebrafish

Predicted Reactivity

  • Cow
  • Sheep
  • Chicken
  • Rabbit
Overview
Catalog # bs-1165R-PE
Product Name Beta catenin Polyclonal Antibody, PE Conjugated
Applications WB, FCM
Reactivity Human, Mouse, Rat, Pig, Zebrafish
Predicted Reactivity Cow, Sheep, Chicken, Rabbit
Specifications
Conjugation PE
Host Rabbit
Source KLH conjugated synthetic peptide derived from human Beta catenin
Immunogen Range 661-781/781
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Gene ID 1499
Swiss Prot P35222
Subcellular location Cytoplasm, Nucleus, Cell membrane
Synonyms CTNNB; MRD19; armadillo; Catenin beta-1; Beta-catenin; CTNNB1; OK/SW-cl.35; PRO2286
Background Key downstream component of the canonical Wnt signaling pathway. In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome. In the presence of Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, where it acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. Involved in the regulation of cell adhesion. Acts as a negative regulator of centrosome cohesion. Involved in the CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. Blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2. Disrupts PML function and PML-NB formation by inhibiting RANBP2-mediated sumoylation of PML.
Application Dilution
WB 1:300-5000
FCM 1:20-100